Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNEU-LINK: V114 safety and tolerability in healthy infants
2018-003308-38Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2018
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 15-valent conjugate vaccine and Prevnar 13 in pneumococcal disease (2 arms), sponsored by Merck & Co. Primary endpoint: Adverse events following any vaccination with V114. Started Nov 2018; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccinePrevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2018-003308-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003308-38.